Objectives: To determine the ability of voriconazole to inhibit the formation of biofilms.
Introduction
Biofilms are structured microbial communities attached to surfaces, connected by water channels and encapsulated within a highly hydrated extracellular matrix mostly composed of polysaccharides and proteins. 1 Candida spp., particularly Candida albicans, the most important causative agent of candidiasis and the fourth most frequent nosocomial infection worldwide, are recognized as major agents of hospital-acquired fungal infection. 2 Many Candida infections involve the formation of biofilms on implanted devices. 3 -5 Candida cells in biofilms (sessile cells) display more resistance to antifungal agents than their freeliving (planktonic) counterparts. 6, 7 This increased resistance of Candida spp. cells is not entirely understood and is likely to be due to multifactorial phenomena. For instance, it has been suggested that resistance may be related to contributions from the extracellular matrix (preventing active drug diffusion), the physiological state (slow growth rate) of sessile cells, activation of drug efflux pump genes (CDR and MDR) whose products are located in the cell membrane, sterol perturbations, high cellular density within the biofilm, the presence of persister cells and/or differential gene expression patterns in biofilm cells. 8 -11 Because biofilms are difficult to eradicate with conventional antifungal therapy and represent a continuous focus of infection, in many cases removal of the contaminated device is necessary to cure these infections, but sometimes the device is essential for the patient and so this cannot be done. 12 Therefore, it is fundamental to develop new approaches to manage Candida biofilmassociated infections.
Azoles, including voriconazole, have shown no activity against pre-formed Candida spp. biofilms. 13 -15 Mukherjee et al. 16 demonstrated that fluconazole-resistant biofilms could be explained by the high expression of efflux pumps at early stages of biofilm formation, and by low ergosterol levels at intermediate and mature phases; or they could be due to the binding of azoles to glucans in the biofilm matrix as Nett et al. 17 suggested. Although azoles have no activity against Candida biofilms, some studies have reported the ability of fluconazole, caspofungin and other substances [terpenes, EDTA and non-steroidal anti-inflammatory drugs (NSAIDs)] to prevent biofilm formation when the surface on which it is formed is treated previously with these drugs, or when biofilms are formed in their presence. 18 -23 Voriconazole is a triazole developed for the treatment of life-threatening fungal infections and is available for both oral and intravenous administration, the oral formulation having excellent bioavailability. It displays clinical efficacy in patients with fluconazole-resistant and -susceptible Candida infections. 24 The FDA and the European Medicines Agency have approved voriconazole for the treatment of fluconazole-resistant invasive Candida infections and candidaemia in non-neutropenic patients. In the most recent Infectious Diseases Society of America (IDSA) guidelines it was recommended as alternative therapy in the treatment of invasive candidiasis in non-neutropenic patients with a good evidential support (A-I). 12 The aim of this study was to determine the ability of voriconazole to inhibit the formation of biofilms both (i) in the presence of the drug, and (ii) on surfaces previously coated with this azole.
Materials and methods

Isolates and growth conditions
A total of 38 clinical isolates of Candida spp. {8 C. albicans, 10 Candida tropicalis, 10 Candida glabrata, 10 Candida parapsilosis complex [3 Candida orthopsilosis (Co-265, Co-269 and Co-272) and 7 Candida parapsilosis sensu stricto]} and the reference strains ATCC 90028 and ATCC 64548 of C. albicans, all of them biofilm producers, were studied. Clinical isolates were collected from blood specimens obtained from patients admitted to Hospital La Fe, Valencia (Spain). The identification of isolates was carried out by metabolic properties (Vitek 2, bioMérieux, Marcy l'Étoile, France). Isolates were stored in distilled sterile water until utilization. Prior to analysis each isolate was subcultured twice on Sabouraud dextrose agar (SDA) plates to ensure viability.
The ability of isolates to form biofilm was previously assessed and reported by Valentín et al. 25, 26 Molecular identification of the C. parapsilosis and C. glabrata complex
The identities of the C. parapsilosis complex, as well as the C. glabrata complex, were performed by PCR as described previously. 27 
Biofilm formation
Biofilms were formed in the wells of microtitre plates using the method described by Ramage et al. 28 with some modifications. Isolates were propagated in yeast peptone dextrose (YPD) medium. Tubes containing 2 mL of YPD were inoculated with cells from a 24 h growth on SDA and incubated overnight in an orbital shaker (100 rpm) at 308C. All cells grew as budding yeast under these conditions. Cells were then harvested by centrifugation, washed three times in sterile PBS (Sigma-Aldrich, Madrid, Spain) and resuspended in PBS. The suspension was spectrophotometrically adjusted to 45% of transmittance at 530 nm, which corresponds to an approximate concentration of 1×10 7 cells/mL (stock cell suspension). Standardized cell suspension was obtained by making a 1/10 dilution of the stock cell suspension in RPMI 1640 medium supplemented with L-glutamine and buffered with MOPS acid (SigmaAldrich). Biofilms were formed by pipetting 100 mL of the standardized cell suspension (1×10 6 cells per mL) into selected wells of sterilized polystyrene flat-bottomed 96-well microtitre plates (Microtest TM tissue culture plate, Becton Dickinson, Madrid, Spain) and incubating for 24 or 48 h at 378C in order to obtain both young and mature biofilms, respectively. After biofilm formation, the medium was aspirated, and non-adherent cells were removed by washing the biofilms three times in sterile PBS.
Quantification of biofilm
Biofilm formation by Candida spp. was quantified using tetrazolium (XTT) reduction assays. The principle is based upon the reduction of XTT (Sigma-Aldrich) to a water-soluble formazan product by mitochondrially active yeasts in the presence of menadione, an electron-coupling agent. The tetrazolium formazan produced was then measured spectrophotometrically. XTT was prepared as a saturated solution at 0.5 mg/mL in Ringer's lactate. This solution was sterilized through a 0.22 mm pore filter and stored at 2708C. Prior to each assay, an aliquot of stock XTT was thawed, and menadione (10 mM in acetone; Sigma-Aldrich) was added to a final concentration of 1 mM. Then, 100 mL of XTT/menadione was added to each well, and microtitre plates were incubated in the dark for 2 h at 378C. The colorimetric change (reflecting the metabolic activity of the sessile cells) was measured in a microtitre plate reader at 492 nm (PR3100 TouchScreen, Bio-Rad, Marnes-la-Coquette, France).
Antifungal agent
Voriconazole (Pfizer Pharmaceuticals Group, New York, NY, USA) was dissolved in DMSO; further dilutions were prepared in standard RPMI 1640 medium (Sigma-Aldrich).
Antifungal susceptibility testing in planktonic cells
MICs for planktonic cells were determined by the CLSI M27-A3 broth microdilution method. 29 C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were used as quality controls. Voriconazole concentration ranged from 0.008 to 4 mg/L. MIC was defined as the lowest drug concentration that caused a reduction of growth ≥50% compared with the control (incubated in the absence of drug) after 24 h of incubation.
Antifungal susceptibility testing in sessile cells
Voriconazole was added to 24 and 48 h biofilms in serially double-diluted concentrations (16 to 0.03 mg/L), and the biofilms were incubated for a further 48 h at 358C. Antifungal-free wells and biofilm-free wells were also included to serve as positive and negative controls, respectively. Sessile MICs (SMICs) were determined at 50% metabolic inhibition with respect to control (without voriconazole) by using the XTT reduction assay described above. Testing of these isolates was performed in quadruplicate and on at least two different days.
Influence of voriconazole on the development of Candida biofilms
The ability of voriconazole to prevent biofilm formation was assessed using two approaches: (i) forming the biofilms in the presence of the antifungal agent by inoculating the 96-well microplates with the standard inoculum plus voriconazole at 0.25 or 0.06 mg/L (low and medium; concentrations that inhibited the majority of isolates assayed in planktonic form and which, furthermore, are reached in serum); and (ii) forming the biofilms on wells previously treated with the drug. This pretreatment was performed by adding 100 mL of voriconazole at different concentrations (16, 4, 1, 0.25 and 0.06 mg/L) in RPMI 1640 medium to selected wells, and incubating overnight at 48C. After this, voriconazole was aspirated, and the wells were washed once with sterile PBS. The microtitre plates were then seeded with the standard inoculum (10 6 cells/ mL) and incubated for 24 h at 378C to allow biofilm formation. For procedure (i) a total of 16 isolates were tested (4 C. albicans, 4 C. tropicalis, 4 C. glabrata and 4 C. parapsilosis sensu stricto), whereas for procedure (ii) all isolates where included. As controls, the same process was carried out using an inoculum without voriconazole in procedure (i) and in untreated plates in procedure (ii). After biofilm formation, the medium was aspirated and washed three times in sterile PBS, and the extent of biofilm formation was assessed by the XTT reduction assay. Four replicate biofilms were included for each isolate, and experiments were performed on at least two different days.
Statistical analysis
The inhibitory effect of voriconazole was expressed as the percentage of optical density at 492 nm of biofilms developed in the presence of voriconazole or voriconazole-treated wells with respect to the optical density of control growth. An analysis of variance (ANOVA) and Student's t-test were applied to determine statistical differences between groups. A P-value ≤0.05 was considered statistically significant.
Results
In vitro activity of voriconazole against Candida spp. (Table 1) . Voriconazole showed no activity against pre-formed biofilms of C. albicans, C. tropicalis, C. glabrata and C. parapsilosis complex (SMIC≥ 16 mg/L), except for one C. albicans isolate (Ca-20; SMIC 0.12 mg/L) that was active against the 24 h biofilm.
Effect of the presence of voriconazole on biofilm formation and development
In the presence of voriconazole, biofilm formation was reduced in a concentration-and species-dependent manner. With a voriconazole concentration of 0.06 mg/L, the highest average reduction in metabolic activity compared with the control (absence of voriconazole) was found for C. albicans (63.7%+6.3%), followed by C. parapsilosis sensu stricto (31.7%+35%), C. tropicalis (29.9%+28.5%) and C. glabrata (10.6%+8.9%). This reduction was statistically significant (P,0.05) for the four isolates of C. albicans, one C. tropicalis, two of C. glabrata and three C. parapsilosis sensu stricto isolates. With 0.25 mg/L, the highest average reduction was for C. parapsilosis sensu stricto (79%+8.6%), followed by C. albicans (64.5%+6.3%), C. tropicalis (53.3%+13.1%) and finally C. glabrata (23.8%+11.2%). With this concentration the biofilm reduction was statistically significant (P,0.05) for all isolates examined.
The relationship of the lowest concentration assayed (0.06 mg/L) with the respective planktonic MICs ranged from 1×MIC to 8×MIC for C. albicans and the C. parapsilosis complex, 0.016×MIC to 8×MIC for C. tropicalis, and 0.016×MIC to 1×MIC for C. glabrata.
Effect of pre-treatment with voriconazole on biofilm formation and development
Coating the wells with voriconazole prior to biofilm formation inhibited surface colonization and consequently biofilm formation in all Candida spp. tested, even at the lowest concentration of voriconazole used (0.06 mg/L), with C. albicans being the species that showed the highest average reduction of biofilm formation at all concentrations assayed (Figure 1) . The biofilm reduction was .40% at ≥0.25 mg/L depending on the isolate (compared with untreated control wells) and .60% at ≥1 mg/L, while for C. tropicalis ≥4 mg/L was required to obtain the same percentage decrease. C. glabrata and C. parapsilosis complex were the organisms least affected by the voriconazole pre-treatment, achieving only a reduction of 20% -30% after surface treatment of the wells with 4 mg/L (Figure 1) . Nevertheless, inhibition of biofilm formation was .45% for all Candida spp. at the highest concentration of voriconazole tested (16 mg/L). The decrease in biofilm formation was statistically significant (P,0.05) in 7 of the 10 C. albicans isolates at all concentrations of voriconazole tested. For the other three isolates (Ca-03, Ca-18 and Ca-20), reduction was significant at ≥0.25 mg/L (Table 1 ). For C. tropicalis, the reduction of biofilm formation was significant (P,0.05) for six isolates with ≥0.25 mg/L (Table 1 ) and for three isolates (Ct-15, Ct-20 and Ct-32) at ≥1 mg/L. Interestingly, for one isolate (Ct-45, voriconazole MIC≤ 0.008), the reduction was significant only when the wells were pre-treated with 16 mg/L drug. The reduction of C. glabrata biofilm formation was significant for two isolates (Cg-10 and Cg-26) at ≥0.25 mg/L, for another two isolates (Cg-22 and Cg-28) at ≥1 mg/L and for a group of isolates (Cg-2, Cg-9, Cg-21, Cg-23 and Cg-27) with different MICs (range 0.12-4 mg/L) at ≥4 mg/L. Only one isolate (Cg-3) exhibited a significant reduction at all concentrations of voriconazole tested (Table 1 ). In the case of C. parapsilosis sensu stricto, reduction in biofilm formation was statistically significant at all concentrations of the drug assayed for one isolate (Cp-271), for two isolates (Cp-259 and Cp-260) it was at ≥0.25 mg/L, for isolates Cp-263 and Cp-264 it was at ≥1 mg/L, and for Cp-261 and Cp-267 and the three C. orthopsilosis isolates (Co-265, Co-269 and Co-272) it was at ≥4 mg/L (Table 1) . Similarly to what occurs with the formation of biofilms in the presence of voriconazole, the inhibition of biofilm development did not depend on the MIC of the antifungal drug calculated for planktonic cells, and a higher MIC had no correlation with a lower reduction of biofilm formation.
Discussion
The most important biofilm-related infections are those associated with medical devices (pacemakers, prosthetic heart valves, central venous catheters, joint prosthesis, urinary catheters, etc.) essential in modern medical practice. There has been an exponential growth in the number of devices inserted over the last few years. It is estimated that 65% of these infections are related to the formation of biofilms on both biological and inert surfaces; 30 furthermore, Candida biofilm production is linked to higher mortality for patients with candidaemia. 31 Valentín et al.
Consequently, there is not only a strong medical motivation for the development of novel antifungal biofilm strategies but also an economical one, since treatment and/or replacement of devices is costly.
Our study confirms the lack of voriconazole activity against pre-formed Candida biofilms, as reported elsewhere. 13, 32 However, voriconazole displayed the ability to reduce formation of biofilms when it was present from the beginning of the Inhibition of Candida spp. biofilm formation by voriconazole 2421 JAC biofilm process, or when biofilms were allowed to form on surfaces previously coated with the drug. The degree of inhibition (reflected in the XTT assays) depended on the Candida spp., the isolate and the concentration of voriconazole; the highest reduction of biofilm formation being achieved at the highest concentration assayed. The inhibition of biofilm development appeared to be due to a surface modification that perturbed adhesion of fungal cells, or to release of the drug from the coated polystyrene surface on which biofilms formed. Furthermore, we have found that biofilm formation was also inhibited by adding voriconazole to the yeast-cell inoculum at the beginning of the formation process. These results are in agreement with those reported for other antifungal agents. 18, 23 Soustre et al. 19 and Bruzual et al. 21 demonstrated that caspofungin and fluconazole, independently, also induced a decrease in the adherence of Candida cells, as well as in biofilm development when the drugs were initially present in the yeast cultures in assays for biofilm formation. According to these authors, a possible explanation is a change in the properties of Candida cell surface or biomaterial surface, thus perturbing the cellular adherence process.
Different models and many types of plastic materials (polystyrene, polymethylmethacrylate, silicone elastomer, etc.) have been used to study Candida biofilms in vitro, and there is evidence that formation of biofilm depends upon the chemical nature of the substrate. 13, 28, 33, 34 One of the limitations of this study is that biofilm formation was assayed on polystyrene microtitre wells; although this is not a material used in indwelling medical devices, we decided to use these plates because they allow better standardization conditions for the assays and easy implementation. 28 Because Candida device-related infections are difficult to treat and affected devices often have to be removed, which can be hazardous for some patients, it is necessary to control biofilm formation to prevent colonization of biomaterials. This study demonstrates the efficacy of voriconazole in reducing biofilm formation and indicates that this azole may be a good candidate for the prevention of Candida biofilm-related infections. This could be an important benefit mainly in patients where the device cannot be removed, although further studies using impregnated catheter tubing or prosthesis are required to confirm our preliminary results.
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